What medication options are appropriate for a patient with osteoporosis who has sustained a provoked fracture?

Medication Choices for Osteoporosis with Previous Fracture

For osteoporosis with a previous fracture, oral bisphosphonates (alendronate or risedronate) are your first-line treatment choice due to proven fracture reduction, safety profile, and cost-effectiveness. 1, 2

Treatment Algorithm Based on Fracture Risk

Very High Risk Patients (Previous Fracture Present)

Your patient with a previous fracture automatically qualifies as very high risk 1, 2. Here's your treatment hierarchy:

First-Line Options:

• Oral bisphosphonates (alendronate 70 mg weekly or risedronate 35 mg weekly) - strongly recommended for broad-spectrum fracture reduction (vertebral, hip, and non-vertebral fractures by 40-70%, 25-40%, and 40-53% respectively) 3, 4
• Add calcium 1,000-1,200 mg/day and vitamin D 600-800 IU/day 1, 2

When Oral Bisphosphonates Are Not Appropriate:

If your patient has GI contraindications (active esophageal disease, inability to remain upright 30-60 minutes, malabsorption disorders), follow this sequence 1, 2:

1. IV bisphosphonates (zoledronic acid annually) - particularly recommended after hip fracture 5
2. Anabolic agents (teriparatide or abaloparatide) - consider as initial therapy for very high risk; these build bone and show superior vertebral fracture reduction versus bisphosphonates 3, 4
3. Denosumab (60 mg subcutaneously every 6 months) - effective but requires structured "exit strategy" with bisphosphonates to prevent rebound bone loss 1, 6

Critical Consideration for Anabolic-First Strategy

For patients at very high risk (which includes your patient with previous fracture), the 2023 ACR guidelines conditionally recommend starting with anabolic agents (teriparatide/abaloparatide) over antiresorptives 1, 2. This produces larger, more durable BMD gains and superior fracture reduction. However, you must follow with bisphosphonate therapy after completing the anabolic course to maintain gains 6, 4.

Specific Medication Details

Oral Bisphosphonates

• Alendronate 70 mg weekly or Risedronate 35 mg weekly or 150 mg monthly
• Take after overnight fast, with full glass of water, remain upright 30-60 minutes
• Duration: Up to 5-10 years with periodic reassessment 3

IV Bisphosphonates

• Zoledronic acid 5 mg IV annually
• No GI absorption issues, better for adherence concerns
• Duration: Up to 6 years 3

Anabolic Agents

• Teriparatide 20 mcg daily subcutaneous for up to 24 months
• Abaloparatide 80 mcg daily subcutaneous for up to 18 months
• Reduces time to fracture union by approximately 3 weeks 7
• Mandatory follow-up: Transition to bisphosphonate or denosumab to prevent bone loss 6

Denosumab

• 60 mg subcutaneous every 6 months
• No renal dose adjustment needed
• Critical warning: Never stop abruptly - requires structured bisphosphonate transition to prevent multiple vertebral fractures from rebound bone loss 6, 4

Agents to Generally Avoid

• Raloxifene - only reduces vertebral fractures, not hip/non-vertebral; increases VTE and fatal stroke risk 1, 2
• Romosozumab - conditional recommendation against due to increased cardiovascular events (MI, stroke, death) 1, 2

Common Pitfalls to Avoid

1. Don't stop denosumab without bisphosphonate bridge - causes severe rebound bone loss and multiple vertebral fractures 6
2. Don't use bisphosphonates indefinitely - reassess at 5 years (oral) or 6 years (IV) for drug holiday consideration 3
3. Don't forget dental precautions - assess for dental disease before starting bisphosphonates or denosumab due to rare osteonecrosis of jaw risk 8
4. Don't use anabolic agents without planning antiresorptive follow-up - gains are lost without consolidation therapy 6, 9

Monitoring Strategy

• BMD with vertebral fracture assessment: Every 1-2 years during treatment 1, 2
• Switch therapy if: New fracture after ≥18 months of oral bisphosphonate OR ≥10% BMD loss per year 10

The bottom line: Start oral bisphosphonates unless contraindicated. For very high risk with multiple fractures or very low BMD (T-score ≤-3.5), strongly consider anabolic-first strategy followed by bisphosphonate consolidation for optimal fracture prevention.